
    
      A total of 3308 subjects were stratified equally into four age groups and receive either
      influenza vaccine or recombinant hepatitis b vaccine (seen as placebo). Systematic and local
      adverse reactions were reported for 28 d after the vaccination. Antibody levels were detected
      through hemagglutination inhibition assay before vaccination (Baseline) and 28d after the
      vaccination.
    
  